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ABSTRACT
Methicillin-resistant Staphylococcus aureus (MRSA) is a common skin coloniser and less commonly causes
infection. MRSA colonisation should be contained by infection control measures and not treated. MRSA
infections cause the same spectrum of infection as MSSA infections, i.e., skin/soft tissue infections,
bone/joint infections, central IV line infections, and acute bacterial endocarditis (native valve/prosthetic
valve). There is a discrepancy between in-vitro sensitivity and in-vivo effectiveness with MRSA. To treat
MRSA infections, clinicians should select an MRSA drug with proven in-vivo effectiveness, i.e.,
daptomycin. Linezolid, quinupristin/dalfopristin, minocycline, or vancomycin, and not rely on in-vitro
susceptibility data. For MRSA, doxycycline cannot be substituted for minocycline. Linezolid and
minocycline are available for oral administration and both are also effective in treating MRSA CNS
infections. Vancomycin is being used less due to side effects, (increasing MICs/resistance, VISA/VRSA),
and increased VRE prevalence. The most potent anti-MRSA drug at the present time is daptomycin.
Daptomycin is useful when rapid ⁄ effective therapy of MRSA bacteraemia ⁄ endocarditis is necessary.
Daptomycin is also useful to treat persistent MRSA bacteraemias/MRSA treatment failures with other
drugs, i.e., vancomycin. There is no difference in virulence between MSSA and MRSA infections if
treatment is started early and with an agent that has in-vivo effectiveness.
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INTRODUCTION
Since the late 1970s, methicillin-resistant Staphy-
lococcus aureus (MRSA) has been reported as the
cause of outbreaks in hospitals throughout the
world. MRSA was first reported in 1961. Initially,
only outbreaks were recognised, as screening for
methicillin resistance was not routinely per-
formed in hospital laboratories. It was gradually
appreciated that MRSA, like methicillin-sensitive
Staphylococcus aureus (MSSA), could colonise or
infect patients. MRSA strains were not found to
be more virulent than MSSA strains and caused
the same spectrum of infection. MRSA, like
MSSA, primarily colonises the nares and the skin
of individuals. Initially, MRSA infections were
encountered in teaching hospitals, but gradually
MRSA colonisation and infection also spread to
non-teaching hospitals. Currently, MRSA coloni-
sation ⁄ infection is encountered in small commu-
nity hospitals, chronic care facilities and even
within the community. Patients colonised in
hospitals, when discharged, can spread strains
throughout the community and thus colonise or
infect non-hospitalised patients. Conversely,
patients who have been colonised or infected in
the community can introduce MRSA into a
hospital when they are admitted. Many outbreaks
have involved inter-hospital spread from colo-
nised patients or medical staff to other patients,
resulting in either episodic outbreaks or variable
levels of MRSA colonisation ⁄ infection in institu-
tions. Patients who are colonised or infected
represent the MRSA reservoir in hospitals and,
to a lesser extent, in the community [1–3].
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EPIDEMIOLOGY
Colonisation
MRSA colonises the nares and the skin and, to a
lesser extent, the urine or faeces. Hand carriage of
MRSA by medical personnel is important in
patient to patient spread. MRSA colonisation of
respiratory secretions in ventilated patients and in
burn units may contribute to airborne dissemin-
ation via droplets between medical staff and
colonised ⁄ infected patients. MRSA colonisation
is difficult to eradicate compared with the treat-
ment of MRSA infections. Difficulty in the erad-
ication of the carrier state of MRSA relates to the
relatively few antibiotics active against MRSA
that are able to penetrate nasal secretions in
sufficient concentration to eliminate nares coloni-
sation. As a general principle of infectious dis-
ease, colonised patients should not be treated;
treatment should be limited to those who are
infected.
The use of some antibiotics is associated with
an increase in MRSA colonisation, e.g., ceftazi-
dime. An increased prevalence of MRSA is
evident in institutions that rely heavily on the
use of certain antibiotics. The containment of
MRSA-colonised patients primarily depends on
the adherence to proven infection control meas-
ures. The same methods used to control the
spread of MSSA are useful in controlling the
spread of MRSA [2,4–9].
Infection control methods
At the present time, MRSA is an endemic
nosocomial pathogen in many hospitals world-
wide. Patients suspected of being colonised with
MRSA should have their nares, as well as other
appropriate body sites, cultured for MRSA. The
critical infection control containment measure for
MRSA is early recognition of the colonised patient
who presents a greater threat of spreading MRSA
in the hospital than the infected patient. Infected
patients are easily recognised as infected and are
handled with the appropriate precautions. The
colonised patient has no signs or symptoms of
infection, leading to relaxed infection control
measures, and, in turn, patient to patient or




In the early 1960s, when methicillin was introduced
as an anti-staphylococcal antibiotic, the first iso-
lates of MRSA were reported. It was quickly noted
that, in cultures of clinical specimens of MRSA,
there were populations of staphylococci with
varying sensitivity to methicillin. Most isolates in
such specimens were sensitive to methicillin, but a
minority of these MRSA strains were highly resist-
ant. This phenomenon is termed heterogeneous
MRSA resistance. Conversely, homogeneous
resistance indicates uniform resistance to methicil-
lin. Methicillin was quickly replaced by less toxic
anti-staphylococcal penicillins, e.g., oxacillin. For
this reason, oxacillin became the antibiotic used
to detect methicillin resistance. Staphylococcal
strains reported as oxacillin resistant are methicil-
lin resistant [2].
In MRSA susceptibility testing, temperature
has a profound effect. Concerning heterogeneous
MRSA resistance, most isolates that grow at 37C
appear to be sensitive to methicillin. However, if
the incubation temperature is decreased to 25C
or 30C, the number of MRSA isolates will
increase.
If incubation is carried out at high temperature,
i.e., 40C, the majority of heterogeneous MRSA
resistance isolates appear to be sensitive. For this
reason, the incubation of cultures for antibiotic
susceptibility testing should be performed at
35C, which is optimal for the susceptibility
testing of S. aureus. Heterogeneous MRSA resist-
ance is also a time-dependent phenomenon.
Prolonged incubation, i.e., 48 h, is recommended
for the optimal detection of heterogeneous MRSA.
Although 48 h is optimal, 24 h is acceptable and a
24-h incubation period is used routinely in med-
ical clinical laboratories.
Inoculum size is also important in MRSA
testing. A small inoculum may contain mixed
populations of MSSA strains, whereas a larger
inoculum is necessary to detect some isolates with
methicillin resistance. Heteroresistant MRSA
detection is also optimised with increased osmo-
larity of the medium. For this reason, the addition
of sodium chloride (5%) or ammonium sulphate
(7%) optimises MRSA detection.
In-vitro susceptibility testing is also affected by
pH. The detection of methicillin resistance is
suppressed at pH 5.2; therefore, susceptibility
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testing for MRSA should be carried out at a
higher pH.
Disc diffusion is the most widely used
method of MRSA susceptibility testing; alternat-
ively, Mueller–Hinton agar may also be used.
Plates are incubated for 24 h at 35C for best
results. Inhibitory zones should be carefully
examined for isolated colonies or minimal
growth. Intermediate methicillin resistance is a
rare phenomenon amongst isolates. Intermedi-
ately resistant strains usually result from the
hyperproduction of b-lactamase and should be
considered as resistant for clinical purposes. The
broth microdilution technique is also used by
laboratories, but this method is less sensitive for
the detection of heteroresistant MRSA isolates.
Incubation temperatures of 30–35C and the
extension of incubation for 48 h optimise the
detection of MRSA strains. Usually, sodium
chloride is added to the medium to optimise the
detection of methicillin resistance. Five per cent
sodium chloride is the optimal concentration to
detect methicillin resistance and is better than
either 2% or 10% sodium chloride. The inoculum
used should be large and the broth should be
adjusted to a McFarland 0.5 standard of turbidity.
Either oxacillin or nafcillin may be used instead of
methicillin for testing, but other anti-staphylococ-
cal antibiotics, i.e., dicloxacillin or cloxacillin,
should not be used. When using oxacillin for
MIC testing, susceptible strains have a MIC of
£ 2 lg ⁄mL, and those with a MIC of ‡ 4 lg ⁄mL
should be considered as resistant.
Many microbiology laboratories use automated
antimicrobial susceptibility testing systems. The
accuracy of such systems in detecting methicillin
resistance depends on the methodology
employed in the system. The more closely the
methodology resembles that used in standard
non-automated testing, the more likely the results
are to be valid. Any MSSA isolates with unusual
susceptibility patterns, identified with an auto-
mated system of susceptibility testing, should be
re-tested using standard methods.
The usual mode of methicillin resistance, i.e.,
resistance to oxacillin, is due to the acquisition of
the mecA gene that codes for PBP 2a, which has a
low affinity for b-lactam antibiotics. Alternatively,
hyper-b-lactamase-producing strains or modifica-
tion of existing penicillin-binding proteins may
also result in methicillin resistance. In the clinical
laboratory, mecA-positive strains are not distin-
guished from other isolates and are all reported as
MRSA. Some investigators have successfully
detected all types of oxacillin resistance using a
screening procedure, employing cefoxitin or mox-
alactam, testing by disc diffusion. Oxacillin resist-
ance is present if the zone of clearing around a
cefoxitin disc is 27 mm, or is < 24 mm surrounding
a moxalactam disc. In the near future, the molecu-
lar detection of the mecA gene will become the
standard for identifying MRSA. Currently, this
involves a research laboratory procedure, but
hopefully it will become available commercially
in the near future [2,15,16].
CLINICAL PRESENTATION
Overview
During the 1970s, when MRSA infections were
being encountered with increasing frequency, it
was quickly understood that the spectrum of
MRSA paralleled that of MSSA. The other import-
ant lesson from the initial worldwide MRSA
outbreaks in the 1970s was therapeutic rather
than diagnostic. Although the clinical spectrum of
MSSA infections had long been recognised and
effective treatment strategies had been developed,
patients with MRSA did not respond to most
antibiotics used at the time (b-lactams) which,
although reported as being effective in vitro, were
ineffective in vivo. However, from the clinical
perspective, the most common clinical infections
caused by MRSA included surgical wound infec-
tions, both primary and secondary bacteraemias,
intra-abdominal ⁄pelvic abscesses, osteomyelitis,
prosthetic joint infections and, rarely, nosocomial
pneumonias. Initially, it was thought that,
because patients with MRSA infections did not
respond to antibiotics, MRSA infection was some-
how different from its MSSA counterpart. This
was later shown to be a result of differences in the
effectiveness of therapeutic agents rather than a
different spectrum of infection or a more virulent
strain of S. aureus [2,17–20].
Sites commonly colonised by MRSA but
uncommonly infected
MRSA, being part of the skin flora, may colonise
any mucosal surface contiguous with MRSA-
colonised skin. Accordingly, MRSA may colo-
nise wounds and burns, as well as respiratory
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secretions, urine and faeces. MRSA infections
involving the genitourinary system, excluding
haematogenously derived MRSA abscesses, are
distinctly unusual. S. aureus is not a normal part
of the faecal flora in patients who have not been
treated with antibiotics or who have not been
previously hospitalised. If such patients become
colonised, they do not develop manifestations of
gastrointestinal infection. S. aureus has long been
known to be a cause of lung abscesses. Sta-
phylococcal lung abscesses may occur from
staphylococcal bacteraemia or from a contiguous
source or staphylococcal chest wall infection,
resulting in staphylococcal empyema. S. aureus,
both MSSA and MRSA, frequently colonises the
respiratory secretions of intubated patients on
ventilators. Colonisation of respiratory secre-
tions is common after prolonged hospitalisation
and broad-spectrum antimicrobial therapy,
which eliminates much of the normal flora,
permitting MRSA to become the predominant
colonising organism in respiratory secretions.
S. aureus hospital-acquired pneumonia is rare,
compared with MRSA colonisation of respirat-
ory secretions, which is a daily occurrence.
Staphylococcal pneumonia has long been recog-
nised as a complication of viral influenza. Either
MSSA or MRSA may be associated with sta-
phylococcal pneumonia in this context [1–3,19]
(Table 1).
Sites commonly infected ⁄ colonised
Skin and soft tissue infections
Skin and soft tissue infections are clearly the most
common clinical MRSA infection. Infection may
be limited to the upper layers of the dermis, e.g.,
cellulitis, or may involve deeper structures, e.g.,
soft tissue abscesses. Staphylococcal skin infec-
tions may be differentiated clinically from Group
A streptococcal skin infection by the presence of
bullae and the absence of systemic symptoms.
High fever, chills and lymphangitis indicate a
Group A streptococcal aetiology. Staphylococcal
abscesses of the soft tissues occur following blunt
or open trauma and may be due to MSSA or
MRSA. Staphylococcal soft tissue abscesses are
common in patients with diabetes mellitus and
may be due to MSSA or MRSA. Staphylococcal
abscesses may be accompanied by high fever and
chills. With staphylococcal cellulitis, chills are not
prominent, in contrast with streptococcal celluli-
tis. MRSA may also present as toxic shock
syndrome in patients colonised or infected with
toxigenic strains of MRSA [1,18].
Bone and joint infections
S. aureus is the most common pathogen in bone
and joint infections. Septic arthritis and acute
osteomyelitis are most frequently due to S. aureus.
Bone and joint infections may be due to either
MSSA or MRSA, depending on local geographic
patterns. The clinical presentation of MRSA septic
arthritis or osteomyelitis is indistinguishable from
similar infections caused by other organisms.
Prosthetic joint infections, usually involving
the hip or knee, are most often caused by strains
of coagulase-negative staphylococci. However,
S. aureus is second only to the coagulase-negative
staphylococci as an important pathogen in pros-
thetic joint infections. MRSA may affect knee or
hip prostheses. In contrast with low virulence
organisms, e.g., the coagulase-negative staphylo-
cocci, S. aureus is more likely to present as acute
prosthetic joint infection [2,19,21].
Endovascular infections
Staphylococcal endocarditis usually presents as
acute bacterial endocarditis (ABE). The increase in
MRSA ABE usually parallels the general increase
in MRSA in the geographical area of patients.
Staphylococcal ABE may occur on normal valves
and result from a staphylococcal bacteraemia.
Nosocomial ABE may occur in patients recently
subjected to intracardiac monitoring devices.
Staphylococcal endocarditis has also been related
to intravascular catheter or pacemaker wires and
may involve normal or prosthetic heart valves.
Staphylococcal ABE occurs primarily in intraven-
ous drug abusers (IVDAs). Septic emboli are
common in these patients and there is a predom-
inance of right-sided valvular involvement. The
prognosis is better for IVDAs than for normal
hosts with a similar extent of intracardiac infec-
tion [2,18].
Table 1. Spectrum of MRSA infection
COMMON UNCOMMON
d Skin/soft tissue infections d Skin ⁄ soft tissue abscesses
d Bone/joint infections d Intra-abdominal abscesses
d Central IV-line infections d Perinephric/intra-nephric abscesses
d Native valve endocarditis d Pelvic abscesses
d Prosthetic valve endocarditis d Lung abscesses
d CNS shunt infections d Ventilator-associated pneumonia (rare)
d Meningitis/brain abscess
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Intravenous line infections are directly related
to medical progress, as lines have become
essential in providing access and for monitoring
patients. However, these devices bypass normal
defence mechanisms, e.g., the skin. The skin is
often colonised with staphylococci, which may
gain access to the catheter and bloodstream via
the catheter entry wound. Staphylococcal bact-
eraemias may be self-limiting or result in
localised or metastatic infection. Some patients
will develop overwhelming septicaemia with a
fatal outcome. The clinical expression of sta-
phylococcal bacteraemia depends on the entry
point of the staphylococcus, the inoculum size,
the underlying condition of the host and host
defence factors. Patients with staphylococcal
bacteraemia or endocarditis usually have a
demonstrable focus of infection involving the
skin ⁄ soft tissues or emanating from a bone ⁄ joint
infection. In the absence of a recognisable
focus for staphylococcal bacteraemia, an endo-
vascular infection, e.g., endocarditis, should be
considered. In a minority of patients with
staphylococcal bacteraemias, no focus can be
demonstrated. Because staphylococcal bacterae-
mias not infrequently eventuate in ABE, early
treatment is essential. If intravenous devices are
thought to be the cause of the bacteraemia, they
should be removed or replaced [7,19].
Vertebral osteomyelitis
Vertebral osteomyelitis is a complication of
S. aureus bacteraemia. Staphylococci in the blood-
stream will lodge in previously damaged joints or
bones. A staphylococcal infection ⁄ abscess often
occurs in a vertebral body ⁄disc previously dam-
aged by arthritis. Elderly patients may not
infrequently develop a paravertebral or epidural
abscess following staphylococcal bacteraemia as
the initial manifestation of vertebral osteomyelitis
[2,18,22].
THERAPY OF MRSA INFECTIONS
General concepts
The therapeutic approach to patients with MRSA
infection depends on the site of the infection and
the choice of antimicrobial agent with in-vivo
activity against MRSA. As with other infectious
diseases, the severity of the infection has import-
ant prognostic implications, but is not an import-
ant factor in antibiotic selection. The site of
infection, and the removal of an infected device
or drainage of an abscess, are more important
than antimicrobial therapy, as in the case of other
staphylococcal infections [2] (Table 2).
Skin ⁄ soft tissue infections and bone ⁄ joint
infections
The non-medical treatment of skin ⁄ soft tissue
infections and bone ⁄ joint infections due to MRSA
is the same as that for MSSA infections. The
surgical drainage of an abscess is as important as
appropriate antimicrobial therapy. The drainage
of septic joints is important to minimise damage
to the synovium and articulating surfaces. Direct
instillation of antibiotic into the joint is unneces-
sary with agents that penetrate well into synovial
fluid. The treatment of acute osteomyelitis, usu-
ally due to S. aureus, is entirely medical with
appropriate anti-staphylococcal therapy. Chronic
osteomyelitis may be due to S. aureus, but is more
frequently due to aerobic Gram-negative bacilli.
However, if it is determined that chronic osteo-
myelitis is staphylococcal, appropriate surgical
debridement should be carried out. Without
adequate surgical debridement, cure of chronic
osteomyelitis is not possible with antimicrobial
therapy alone [2,20].
Central intravenous line infections
The treatment of intravenous line infection due to
MRSA first depends on the establishment of a
diagnosis. MRSA line infections present with
otherwise unexplained fevers, and a catheter
entry site may or may not appear to be infected.
Table 2. MRSA facts and fallacies
Fallacies Facts
d MRSA colonization is
not important.
d MRSA colonization is the primary
mode of spread from patient to patient,
and from patient to staff, and staff to patient.
d MRSA colonization
should be treated.
d MRSA colonization is difficult to eliminate,
and should not usually be treated.
d Antibiotics reported as
sensitive to MRSA in vitro
may be used for therapy.
d Only daptomycin, linezolid, quinupristin/
dalfopristin, minocycline, and vancomycin, are
consistently effective against MRSA in vivo.
d MRSA strains are more
virulent than MSSA strains.
d MRSA causes the spectrum of infection
as MSSA, and are not more virulent if treated
promptly ⁄properly.
d IV therapy for MRSA is more
effective than oral therapy.
d IV and PO therapy are equally efficacious if
the oral agent has high degree of bioavailability
and the same PK/PD as its IV counterpart.
IV ¼ intravenous; PO ¼ oral; PK ¼ pharmacokinetic; PD ¼ pharmacodynamic
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If the catheter insertion site looks infected, the
central intravenous catheter should be removed
as soon as possible. If no other source of fever can
be determined and the intravenous central line
has been in place for an extended period of time,
i.e., > 2 weeks, a presumptive diagnosis of intra-
venous line infection should be entertained. The
diagnosis of intravenous line infection due to
MRSA or other agents is confirmed by semi-
quantitative catheter tip culture after removal; if
the removed catheter tip grows ‡ 15 colonies
using the Maki or Cleary semi-quantitative tech-
nique, and the patient has blood cultures drawn
at the same time as the central line is removed,
which are positive for the same organism, intra-
venous line infection is confirmed. If a central line
tip is removed with possible intravenous line
infection as the diagnosis, and the catheter tip is
negative or grows £ 15 colonies, the criteria are
not met. Similarly, a positive intravenous catheter
tip culture with ‡ 15 colonies occurring in associ-
ation with negative blood cultures is not diagnos-
tic of intravenous line infection. The likelihood of
central line infection is a function of time, assu-
ming that an aseptic technique has been used
during catheter insertion. After the diagnosis has
been confirmed, the main therapeutic interven-
tion is removal of the central catheter. Because
intravenous line infections due to S. aureus, either
MSSA or MRSA, have the potential to cause
endocarditis, antimicrobial therapy is given for 2–
4 weeks following central line removal. The dur-
ation of therapy for MSSA and MRSA line
infections has not been determined [19,23,24].
Acute bacterial endocarditis
Staphylococcal endocarditis may occur as a result
of a staphylococcal bacteraemia seeding a normal
valve, e.g., the aortic valve, or as a result of
damage to the endothelium or heart valves from
an intravascular device positioned in the right
heart. The other group of patients with an
increased incidence of staphylococcal endocardi-
tis are IVDAs. The clinical presentation of sta-
phylococcal ABE in IVDAs is milder and subacute
in contrast with the fulminant course of ABE in
normal hosts. The effective treatment of staphylo-
coccal ABE depends on an accurate diagnosis, i.e.,
positive blood cultures plus a cardiac echocardi-
ogram that demonstrates one or more vegetations
or intramyocardial abscesses. A myocardial
abscess, depending on its position, may present
as fever of unknown origin, valvular dysfunction
or various degrees of heart block. If the staphylo-
coccal ABE is due to an intravascular device in the
right heart, it should be removed. Myocardial
abscesses should be drained if they are large and
surgically accessible. Cardiac valves, which are
incompetent, should also be replaced surgically
with prosthetic valves. The antimicrobial therapy
for staphylococcal endocarditis differs according
to the setting. IVDAs with staphylococcal ABE
have been managed using oral anti-staphylococ-
cal therapy with excellent results. Although the
initial treatment of endocarditis in non-IVDAs has
traditionally been intravenous, there is a trend
towards treatment of patients with oral antibiotics
that have favourable pharmacokinetics, making
oral treatment as effective as intravenous therapy
at the present time, daptomycin is arguably the
most effective drug for MRSA ABE ⁄PVE [2,18].
Staphylococcal meningitis
Staphylococcal meningitis may occur as a com-
plication of staphylococcal ABE as the result of
meningeal seeding. Staphylococcal brain absces-
ses may occur following open or closed neuro-
surgical trauma. Staphylococcal shunt infections
may complicate neurosurgical procedures. Small
staphylococcal abscesses of the brain may be
managed medically, but large abscesses should be
drained if neurosurgically possible. Infected cen-
tral nervous system (CNS) shunts should be
removed and, if due to MSSA or MRSA, anti-
MRSA therapy that penetrates the cerebrospinal
fluid in therapeutic concentrations should follow,
i.e., linezolid, minocycline or high dose intrathecal
vancomycin (30 mg ⁄kg ⁄day) [2,18,19].
ANTI-MRSA ANTIMICROBIAL
AGENTS
The therapy of MRSA infections is complicated by
the fact that relatively few agents with proven
in-vivo efficacy against MRSA are available. While
many antibiotics appear to have anti-MRSA activ-
ity in vitro, they are ineffective in vivo or only
sporadically effective. Therefore, clinicians should
not rely on in-vitro susceptibility testing to deter-
mine antibiotic selection for anti-MRSA therapy.
There are only four drugs that have demonstrated
consistent activity against MRSA in vivo. Four
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antimicrobial agents with a consistent and high
degree of anti-MRSA activity are quinupris-
tin ⁄dalfopristin, minocycline, daptomycin, line-
zolid and vancomycin. The anti-MRSA effects of
trimethoprim–sulfamethoxazole (TMP-SMX) are
variable. Rifampin is a potent anti-staphylococcal
antibiotic, but its activity in MRSA infections
remains to be demonstrated [21,22,24–30].
Given the four agents available to treat MRSA
infections, the clinician must choose on the basis
of the assessment of several factors. Antibiotic
selection for MRSA infection or any other infec-
tion depends on an assessment of the activity of
the agent, its pharmacokinetics, its safety profile,
its resistance potential and its cost to the patient
or institution.
The availability of the antibiotic as an oral
formulation as well as an intravenous prepar-
ation is also important. Oral therapy is usually
less expensive than its intravenous counterpart,
and provides the clinician and patient with
greater flexibility in an effective therapeutic
regimen. Daptomycin, vancomycin, and qui-
nupristin ⁄dalfopristin are only available intra-
venously for the treatment of MRSA infections.
Minocycline and linezolid are available in both
oral and intravenous formulations. The use of
quinupristin ⁄dalfopristin is occasionally compli-
cated by painful myalgias. Vancomycin has the
advantage of a long therapeutic experience, but
has disadvantages, i.e., limited penetration into
bone and CSF (15% of simultaneous serum
levels), and a variety of side-effects. Minocycline
has the advantage of relatively low cost, and
has the ability to penetrate the CNS. Minocy-
cline has been used primarily to treat MRSA
endocarditis in IVDAs and staphylococcal CNS
infections.
Linezolid is available intravenously and orally,
which is an important advantage. Orally adminis-
tered linezolid has the same pharmacokinetic
profile, resulting in the same serum ⁄ tissue concen-
trations, as the same dose given intravenously.
Linezolid also has the advantage of excellent CNS
penetration. Linezolid has been used successfully
to treat MRSA ABE, CNS infections and a wide
variety of MRSA infections not involving the heart
or CNS, e.g., MRSA hospital-acquired pneumonia.
One advantage of linezolid is its relatively low cost
when given orally, compared with intravenously
administered vancomycin [2,18,30] (Table 3).
CONCLUSION
MRSA has emerged worldwide as an important
nosocomial pathogen since the 1970s. Over the
years, laboratory methodology to detect methicil-
lin resistance has been widely introduced and
standardised, permitting accurate detection of
MRSA strains from clinical specimens. Epidem-
iologically, MRSA occupies the same ecological
niche in hospitals and the community as does
MSSA. As S. aureus is a normal denizen of the
nares ⁄ skin, it is not surprising that most infec-
tions due to MRSA are introduced into the skin,
soft tissues or bloodstream from a skin source. It
has also become apparent that, as with MSSA, the
majority of MRSA isolates represent colonisation
rather than infection. Because colonisation is the
usual mode of MRSA expression in the clinical
Table 3. Clinical comparison of anti-MRSA antibiotics
Anti-MRSA Agent Usual Adult Dose* Side Effects Advantages Disadvantages
Daptomycin 4 mg/kg (IV) q24 h
(skin ⁄ soft tissue)
6 mg ⁄ kg (IV) q24 h
(bacteraemia ⁄ endocarditis)
None Most effective/rapidly bactericidal
MRSA antibiotic
Resolves MSSA/MRSA bacteremias faster
than vancomycin/other MRSA drugs
No › VRE
q24 h dosing CrCl >30; q48 h dosing CrCl £30
Little/no resistance potential
No PO form
Linezolid 600 mg(IV/PO)ql2 h Transient/reversible Available PO and IV Relatively expensive IV
Quinupristin/
dalfopristin
7.5 mg/kg (IV) q8 h Thrombocytopenia
Painful myalgias
Proven effectiveness No PO form
Painful myalgias
Q8h dosing
Minocycline 100–200 mg(IV/PO)q12 h Skin discoloration with
prolonged use
Effective in ABE in IVDAs Available PO and IV
Excellent CNS penetration Inexpensive
Limited experience
Vancomycin lg(IV)ql2 h Neutropenia Thrombocytopenia
‘‘Red Man’’ syndrome
Long clinical experience › MICs/resistance (VISA/VRSA)
No PO form for MRSA
› VRE
IV vancomycin more expensive than
PO linezolid
*Normal renal/hepatic function
Adapted from: Cunha BA. Antibiotic Essentials. Royal Oak, MI, 2005.
Cunha Methicillin-resistant Staphylococcus aureus 39
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11 (Suppl. 4), 33–42
context, the infection control implications are
important. TMP-SMX and mupirocin nasal oint-
ment have been used with variable success, but
infection control methods remain the preferred
way to minimise MRSA transmission within an
institution. Another factor influencing the preval-
ence of MRSA in an institution is the selection of
antibiotics on the hospital formulary. Certain
antibiotics are known to increase the prevalence
of MRSA, e.g., ciprofloxacin, ceftazidime, imipe-
nem. Institutions with high rates of prevalence of
MRSA should consider restricting or reducing the
usage of these agents after other methods have
been tried.
The relative proportion of MSSA vs. MRSA
causing colonisation ⁄ infection varies by geo-
graphical area. The empirical treatment of
S. aureus infections depends on local epidemio-
logical patterns. If the majority of S. aureus strains
in a community are MSSA, initial empirical
therapy should be with an agent which has a
high degree of activity against MSSA. Conversely,
if the majority of S. aureus isolates in a community
are of the MRSA variety, initial empirical therapy
should be with one of the agents known to be
effective against MRSA in vivo [2,30].
With MRSA, unlike MSSA, there is a discrep-
ancy between the in-vitro susceptibility and in-
vivo effectiveness. Clinicians should be aware
that they should not rely on susceptibility testing
to select an antibiotic to treat MRSA infections.
Treatment options are based on the antibiotic
activity, pharmacokinetics, resistance potential,
side-effect profile and cost. The preferred MRSA
drugs are daptomycin, linezolid or quinupris-
tin ⁄dalfopristin. Linezolid or minocycline may be
initially prescribed orally, or prescribed orally to
complete an intravenous regimen. The primary
use of minocycline in the treatment of MRSA is
for ABE and IVDAs, for CNS infections and for
those patients unable to tolerate vancomycin high
dose (30 mg ⁄ kg ⁄day) or linezolid.
Daptomycin is replacing vancomycin as the
preferred drug for serious ⁄ systemic MRSA infec-
tions. The prevalence of vancomycin-resistant
enterococci increases as a result of vancomycin
therapy, and this effect is most pronounced with
intravenous, as opposed to orally administered,
vancomycin. The other disadvantage of vancomy-
cin is that it cannot be given orally for serious ⁄ sys-
temic MRSA infections. Oral vancomycin use is
limited to the treatment of Clostridium difficile
diarrhoea. Although vancomycin may be used to
treat CNS staphylococcal infections, linezolid,
administered both orally and intravenously,
shows better CNS penetrance. Daptomycin is
effective against MSSA and MRSA. Daptomycin
is bacterial and appears to clear MRSA bacteremias
more rapidly than other anti-MRSA antibiotics.
The daptomycin dose is 4 mg/kg/day (IV) for
skin/soft tissue infections, and 6 mg/kg/day (IV)
for S. aureus bacteremias or endocarditis. The dose
of daptomycin is the same in mild/moderate renal
insufficiency (CrCl > 30 ml/min), but either the 4-
Fig. 1. MRSA PVE complicated by
aortic paravalvular abscess [36].
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or 6-mg/kg (IV) dose should be given every 48 h if
the CrCl < 30 ml/min. The more serious/life
threatening the MRSA infection, the more clin-
icians should select daptomycin. Daptomycin is
also useful in MSSA/MRSA unresponsive to other
agents (Figure 1).
Surgical drainage or device removal is as
important as antimicrobial therapy in the treat-
ment of MRSA infections, and remains the cor-
nerstone of non-antibiotic therapy [2,30,32–37].
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